JP2022512987A - タンパク質キナーゼc活性化剤で処理された幹細胞またはその培養物を含む自己免疫疾患の予防または治療用薬学的組成物 - Google Patents
タンパク質キナーゼc活性化剤で処理された幹細胞またはその培養物を含む自己免疫疾患の予防または治療用薬学的組成物 Download PDFInfo
- Publication number
- JP2022512987A JP2022512987A JP2021525208A JP2021525208A JP2022512987A JP 2022512987 A JP2022512987 A JP 2022512987A JP 2021525208 A JP2021525208 A JP 2021525208A JP 2021525208 A JP2021525208 A JP 2021525208A JP 2022512987 A JP2022512987 A JP 2022512987A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- treated
- activator
- protein kinase
- stem cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 56
- 102000003923 Protein Kinase C Human genes 0.000 title claims abstract description 44
- 108090000315 Protein Kinase C Proteins 0.000 title claims abstract description 44
- 239000012190 activator Substances 0.000 title claims abstract description 39
- 208000023275 Autoimmune disease Diseases 0.000 title claims abstract description 34
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 18
- 230000002265 prevention Effects 0.000 title claims abstract description 15
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 88
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 62
- 238000004519 manufacturing process Methods 0.000 claims description 21
- 230000014509 gene expression Effects 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 19
- 201000001981 dermatomyositis Diseases 0.000 claims description 16
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims description 14
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 230000030833 cell death Effects 0.000 claims description 11
- 206010025135 lupus erythematosus Diseases 0.000 claims description 10
- VDJHFHXMUKFKET-UHFFFAOYSA-N Ingenol mebutate Natural products CC1CC2C(C)(C)C2C2C=C(CO)C(O)C3(O)C(OC(=O)C(C)=CC)C(C)=CC31C2=O VDJHFHXMUKFKET-UHFFFAOYSA-N 0.000 claims description 9
- 238000012258 culturing Methods 0.000 claims description 9
- VDJHFHXMUKFKET-WDUFCVPESA-N ingenol mebutate Chemical compound C[C@@H]1C[C@H]2C(C)(C)[C@H]2[C@@H]2C=C(CO)[C@@H](O)[C@]3(O)[C@@H](OC(=O)C(\C)=C/C)C(C)=C[C@]31C2=O VDJHFHXMUKFKET-WDUFCVPESA-N 0.000 claims description 9
- 229960002993 ingenol mebutate Drugs 0.000 claims description 9
- 210000004504 adult stem cell Anatomy 0.000 claims description 8
- 230000028993 immune response Effects 0.000 claims description 6
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 6
- 230000009885 systemic effect Effects 0.000 claims description 6
- MJMJERJFCHYXEM-UHFFFAOYSA-N 5-chloro-N-heptyl-1-naphthalenesulfonamide Chemical compound C1=CC=C2C(S(=O)(=O)NCCCCCCC)=CC=CC2=C1Cl MJMJERJFCHYXEM-UHFFFAOYSA-N 0.000 claims description 5
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 5
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 5
- 239000003018 immunosuppressive agent Substances 0.000 claims description 5
- 230000002757 inflammatory effect Effects 0.000 claims description 5
- -1 6-phenylhexyl Chemical group 0.000 claims description 4
- 230000001363 autoimmune Effects 0.000 claims description 4
- MJQUEDHRCUIRLF-TVIXENOKSA-N bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 claims description 4
- 229960005539 bryostatin 1 Drugs 0.000 claims description 4
- 201000004384 Alopecia Diseases 0.000 claims description 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 3
- 206010003645 Atopy Diseases 0.000 claims description 3
- 208000009137 Behcet syndrome Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 208000004232 Enteritis Diseases 0.000 claims description 3
- 206010015150 Erythema Diseases 0.000 claims description 3
- 208000001640 Fibromyalgia Diseases 0.000 claims description 3
- NUQJULCGNZMBEF-UHFFFAOYSA-N Prostratin Natural products COC(=O)C12CC(C)C3(O)C(C=C(CO)CC4(O)C3C=C(C)C4=O)C1C2(C)C NUQJULCGNZMBEF-UHFFFAOYSA-N 0.000 claims description 3
- 206010043781 Thyroiditis chronic Diseases 0.000 claims description 3
- 231100000360 alopecia Toxicity 0.000 claims description 3
- 208000002399 aphthous stomatitis Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 3
- 231100000321 erythema Toxicity 0.000 claims description 3
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 3
- 230000001861 immunosuppressant effect Effects 0.000 claims description 3
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 208000005987 polymyositis Diseases 0.000 claims description 3
- BOJKFRKNLSCGHY-HXGSDTCMSA-N prostratin Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)C[C@@]3(OC(C)=O)C(C)(C)[C@H]3[C@@H]21 BOJKFRKNLSCGHY-HXGSDTCMSA-N 0.000 claims description 3
- 230000002123 temporal effect Effects 0.000 claims description 3
- 239000003446 ligand Substances 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 229940022663 acetate Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 18
- 230000001225 therapeutic effect Effects 0.000 abstract description 9
- 230000003449 preventive effect Effects 0.000 abstract description 2
- 238000010586 diagram Methods 0.000 abstract 1
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical group C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 78
- 210000004027 cell Anatomy 0.000 description 73
- 241000699670 Mus sp. Species 0.000 description 20
- 230000002441 reversible effect Effects 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 13
- 238000002347 injection Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 238000002965 ELISA Methods 0.000 description 12
- 102100037850 Interferon gamma Human genes 0.000 description 12
- 108010074328 Interferon-gamma Proteins 0.000 description 12
- 210000001744 T-lymphocyte Anatomy 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 210000003734 kidney Anatomy 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 230000012292 cell migration Effects 0.000 description 8
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 8
- 238000003757 reverse transcription PCR Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 101000958041 Homo sapiens Musculin Proteins 0.000 description 7
- 108020004459 Small interfering RNA Proteins 0.000 description 7
- 238000010162 Tukey test Methods 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 102000046949 human MSC Human genes 0.000 description 7
- 210000004379 membrane Anatomy 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 238000001543 one-way ANOVA Methods 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 239000004055 small Interfering RNA Substances 0.000 description 7
- 102000015212 Fas Ligand Protein Human genes 0.000 description 6
- 108010039471 Fas Ligand Protein Proteins 0.000 description 6
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 6
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 6
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 6
- 210000001185 bone marrow Anatomy 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 5
- 108010085238 Actins Proteins 0.000 description 5
- 102000004121 Annexin A5 Human genes 0.000 description 5
- 108090000672 Annexin A5 Proteins 0.000 description 5
- 102000011727 Caspases Human genes 0.000 description 5
- 108010076667 Caspases Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 5
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- YUXMTDYHFPRPLG-UHFFFAOYSA-N 5-chloro-N-(6-phenylhexyl)-1-naphthalenesulfonamide Chemical compound C1=CC=C2C(Cl)=CC=CC2=C1S(=O)(=O)NCCCCCCC1=CC=CC=C1 YUXMTDYHFPRPLG-UHFFFAOYSA-N 0.000 description 4
- 101000840545 Bacillus thuringiensis L-isoleucine-4-hydroxylase Proteins 0.000 description 4
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 description 4
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 description 4
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 4
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 4
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 4
- 101001037255 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Indoleamine 2,3-dioxygenase Proteins 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 230000003915 cell function Effects 0.000 description 4
- 210000004443 dendritic cell Anatomy 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 3
- 101000622304 Homo sapiens Vascular cell adhesion protein 1 Proteins 0.000 description 3
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 3
- 102000013462 Interleukin-12 Human genes 0.000 description 3
- 108010065805 Interleukin-12 Proteins 0.000 description 3
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 3
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 3
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 3
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- BQJRUJTZSGYBEZ-YVQNUNKESA-N phorbol 12,13-dibutanoate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(=O)CCC)C1(C)C BQJRUJTZSGYBEZ-YVQNUNKESA-N 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- SNBCLPGEMZEWLU-QXFUBDJGSA-N 2-chloro-n-[[(2r,3s,5r)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl]acetamide Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CNC(=O)CCl)[C@@H](O)C1 SNBCLPGEMZEWLU-QXFUBDJGSA-N 0.000 description 2
- 208000023328 Basedow disease Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000015023 Graves' disease Diseases 0.000 description 2
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 102100024924 Protein kinase C alpha type Human genes 0.000 description 2
- 101710109947 Protein kinase C alpha type Proteins 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000001378 electrochemiluminescence detection Methods 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 229940125721 immunosuppressive agent Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N serine Chemical compound OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- QGVLYPPODPLXMB-UBTYZVCOSA-N (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b,9,9a-tetrahydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-5H-cyclopropa[3,4]benzo[1,2-e]azulen-5-one Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(O)C(C)(C)[C@H]3[C@@H]21 QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 description 1
- NWNOWCGAHDFNFJ-RUCXOUQFSA-N (2s)-2,5-bis(azanyl)-5-oxidanylidene-pentanoic acid Chemical compound OC(=O)[C@@H](N)CCC(N)=O.OC(=O)[C@@H](N)CCC(N)=O NWNOWCGAHDFNFJ-RUCXOUQFSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000000412 Annexin Human genes 0.000 description 1
- 108050008874 Annexin Proteins 0.000 description 1
- 230000024704 B cell apoptotic process Effects 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100098985 Caenorhabditis elegans cct-3 gene Proteins 0.000 description 1
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 101000804764 Homo sapiens Lymphotactin Proteins 0.000 description 1
- 101000957437 Homo sapiens Mitochondrial carnitine/acylcarnitine carrier protein Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 102100035304 Lymphotactin Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102100038738 Mitochondrial carnitine/acylcarnitine carrier protein Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 241001522306 Serinus serinus Species 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- NFXWJYUDIOHFAW-UHFFFAOYSA-N acetic acid;tetradecanoic acid Chemical compound CC(O)=O.CCCCCCCCCCCCCC(O)=O NFXWJYUDIOHFAW-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000011316 allogeneic transplantation Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000012152 bradford reagent Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000002338 cryopreservative effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 238000012340 reverse transcriptase PCR Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1107—B cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0668—Mesenchymal stem cells from other natural sources
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Reproductive Health (AREA)
- Transplantation (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Gynecology & Obstetrics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
(材料)
MRL/lprマウスは、米国Jackson Laboratory(Bar Harbor,Maine,USA)から購入した。マウスは、12時間の明暗周期(12h light/dark cycle)下で21~24℃および40~60%相対湿度の条件の特定病原菌がない状態で保管された。
IFN-γの測定は、R&D(#DY285-05)で提供された試験方法によって進め、IgMは、IgM ELISA kit(ebioscience,Vienna,Austria)を利用して測定した。ELISA用の96ウェル(well)に捕捉抗体(capture antibody)とコーティングバッファー(coating buffer)を1:250の割合で希釈して4℃で18時間コーティングした。200μlの洗浄溶液(wash solution)を利用して2回洗浄し、ブロッキングバッファー(blocking buffer)250μlをウェル(well)に入れた後、室温で2時間反応させた。その後、200μlの洗浄溶液を利用して2回洗浄し、試料をアッセイバッファー(assay buffer)(1X)に希釈してサンプルを準備した。各ウェル(well)にアッセイバッファー(1x)90μl、検出抗体(detection-antibody)50μlおよびスタンダード(standard)またはサンプル(sample)10μlを入れて室温で3時間反応させた。反応が終わると、洗浄溶液を利用して洗浄した。基質溶液(Substrate solution)100μlを各ウェル(well)に入れた後、5分間反応させ、停止液(stop solution)100μlを入れて反応を中止させた。最後に、450nm~570nmで値を測定した。
細胞溶解バッファー(Cell lysis buffer;Cell signaling technology,Danvers,MA,USA)を利用して細胞を氷(ice)に載置した状態で溶解した。4℃で12000rpmで15分間遠心分離してタンパク質を得た。ブラッドフォード(Bradford)試薬を利用してタンパク質を定量して20μgのタンパク質をSDS-ポリアクリルアミドゲル(polyacrylamide gel)を利用して75Vで電気泳動を実施した。SDS-ポリアクリルアミドゲルを95Vで90分間PVDFメンブレン(membrane)に移した後、0.5%Tween 20が含まれたTBS(TTBS)に5%脱脂粉乳(nonfat dry milk)を添加して1時間ブロッキング(blocking)した。ブロッキング(Blocking)後、1次抗体が含まれた5%BSA/TTBSにメンブレン(membrane)を入れ、4℃で1日間シェイキング(shaking)した。翌日、TTBSでメンブレンを洗浄した後、2次抗体が入っている5%BSA/TTBSにメンブレンを入れて、常温で90分間2次抗体を付着した。TTBSでメンブレンを洗浄し、ECL(Enhanced Chemiluminescence,Amersham Pharmacia Biotech,Piscataway,NJ,USA)とmembraneを反応させた後、Chemi Doc XRS+machine(Bio-Rad,CA,USA)を利用してタンパク質発現程度を測定した。
細胞(Cell)が70~80%のコンフルエンス(confluency)となった時点でTrypsin-EDTA(Gibco)0.125%で処理した後、5%CO2、37℃の条件下に培養した。物質処理24時間後、細胞を回収してTRIZOL reagent(Invitrogen,MD,USA)を利用してトータル(total)RNAを細胞(cell)から分離し、260nmで吸光度の測定を通じてトータルRNA(total RNA)を定量した。
トータル(total)RNA 0.3μgの濃度を利用し、42℃で1時間、95℃で5分間合成した。合成されたcDNA 3μlとプライマー(primer)10pMを利用してポリメラーゼ連鎖反応を行った。この反応の基本過程は、pre-denaturing phase段階を94℃で5分を行い、denaturing phase、94℃で30秒、annealing phase、56℃で30秒、elongation phase、72℃で1分を行い、post-elongation phaseを72℃で5分の条件で実施した。1%アガロースゲル(agarose gel)を作って電気泳動を実施した。
FasL、PD-L1、PD-L2、ICAM1、VCAM1、β-actin、IFN-γ、TNF-α、IL-12、COX-2、iNOS、IDO、TGF-β、CCL2、CCL3、CXCL10、CXCL12に対するmRNAの発現水準をqPCR(quantitative real-time PCR)を通じて分析した。各サンプルの相対的mRNA量は、ハウスキーピング遺伝子(housekeeping gene)であるβ-actinのCt(threshold cycle)と比較した臨界周期(threshold cycle,Ct)を基準として計算された。
冷たいPBSで2回細胞を洗浄後にバインディングバッファー(Binding buffer)に1×106 cell/mlの濃度で細胞を溶解した。その後、5mlカルチャーチューブ(culture tube)に100μlの量を移した後、5μlの量のAnnexin V Apoptosis Detection Kit(BD Pharmingen,USA)を利用して25℃、常温、暗い条件で15分間インキュベーション(incubation)過程を経て細胞を染色した。その後、400μlバインディングバッファー(Binding Buffer)溶液を添加した後に、flow cytometry(CantoII、BD Bioscience)を利用して測定した。
使用されたタプライマー情報は、次の通りである。CCL2 forward primer 5’-ATG AAA GTC TCT GCC GCC CTT CTG T-3’、CCL2 reverse primer 5’-AGT CTT CGG AGT TTG GGT TTG CTT G-3’、CCL3 forward primer 5’-ATG CAG GTC TCC ACT GCT GCC CTT-3’、CCL3 reverse primer 5’-GCA CTC AGC TCC AGG TCG CTG ACA T-3’、CXCL10 forward primer 5’-CCT GCT TCA AAT ATT TCC CT-3’、CXCL10 reverse primer 5’-CCT TCC TGT ATG TGT TTG GA-3’、CXCL12 forward primer 5’-ATG AAC GCC AAG GTC GTG GTC G-3’、CXCL12 reverse primer 5’-TGT TGT TGT TCT TCA GCC G-3’、COX-2 forward primer 5’-TCC TTG CTG TTC CCA CCCAT-3’、COX-2 reverse primer 5’-CAT CAT CAG ACC AGG CAC CA-3’、iNOS forward primer 5’-ACG TGC GTT ACT CCA CCA AC-3’、iNOS reverse primer 5’-CAT AGC GGA TGA GCT GAG CA-3’、IDO forward primer 5’-AGCC TGA TCT CAT AGA GTC TG-3’、IDO reverse primer 5’-TTA CTG CAG TCT CCA TCA CG-3’、TGF-β forward primer 5’-CAG ATC CTG TCC AAG CTG-3’、TGF-β reverse primer 5’-TCG GAG CTC TGA TGT GTT-3’、FasL forward primer 5’-GGA TTG GGC CTG GGG ATG TTT CA-3’、FasL reverse primer 5’-TTG TGG CTC AGG GGC AGG TTG TTG-3’、PD-L1 forward primer 5’-TTG GGA AAT GGA GGA TAA GA-3’、PD-L1 reverse primer 5’-GGA TGT GCC AGA GGT AGT TCT-3’、PD-L2 forward primer 5’-ACA CCG TGA AAG AGC C-3’、PD-L2 reverse primer 5’-AAT GTG AAG CAG CCA AG-3’、ICAM1 forward primer 5’-CGT GCC GCA CTG AAC TGG AC-3’、ICAM1 reverse primer 5’-CCT CAC ACT TCA CTG TCA CCT-3’、VCAM1 forward primer 5’-ATG ACA TGC TTG AGC CAG G-3’、VCAM1 reverse primer 5’-GTG TCT CCT TCT TTG ACA CT-3’、β-actin forward primer 5’-GTG GGG CGC CCC AGG CAC CA-3’、β-actin reverse primer 5’-CTC CTT AAT GTC ACG CAC GA-3’。使用されたマウスプライマーは、INF-γ forward primer 5’-AGC GGC TGA CTG AAC TCA GAT TGT AG-3’、INF-γ reverse primer 5’-GTC ACA GTT TTC AGC TGT ATA GGG-3’、TNF-αforward primer 5’-AGG TTC TGT CCC TTT CAC TCA CTG -3’、TNF-α reverse primer 5’-AGA GAA CCT GGG AGT CAA GGT A-3’、IL-12 forward primer 5’-AGA GGT GGA CTG GAC TCC CGA -3’、IL-12 reverse primer 5’-TTT GGT GCT TCA CAC TTC AG-3’、β-actin forward primer 5’-TGG AAT CCT GTG GCA TCC ATG AAA C -3’、β-actin reverse primer 5’-TAA AAC GCA GCT CAG TAACAG TCC G-3’である。
細胞移動確認のためのイメージ撮影のためにCulture-insert m-dish35mm(ibidi GmbH,Martinsried,Germany)を利用して、左側にMSC(70ml、0.3×106 cells/ml)をシーディング(seeding)し、右側にB細胞70ml、3×106 cells/ml)をシーディング(seeding)した。細胞が安定化すると、insertを除去した後、Biostation IM-Q(Nikon,Toyko,Japan)を利用して撮影した。この実験は、3時間~6時間の間2分間隔で撮影を実施し、データ分析は、Imaris 7.2 software(Bitplane Inc,South Windor,CT USA)を利用した。
B細胞の移動は、5μm insert upper wellを有する24-transwell plates(Costar,Corning,NY,USA)を利用した。PBMCから分離したB細胞(1×105 cells/well,upper chamber)とI3A-treated hMSC(1×103 cells/well,lower chamber)をODNと共に72時間の間トランスウェル(transwell)を利用して共培養を実施した。上澄み液中にあるIgMの水準をELISAを通じて測定した。
実験データ統計分析は、GraphPad Prism 5.0(GraphPad,San Diego,CA,USA)ソフトウェアを利用して分析を実施した。
PBMC(Peripheral blood mononuclear cell)から分離したB細胞(1×105 cells/well)とPMA-処理された(treated)hMSC(1×103 cells/well)をCpG ODN(oligodeoxynucleotides、5μg/ml)と共に72時間の間共培養を実施した後、上澄み液中にあるIgMの水準をELISAを通じて測定した(図1のA)。PBMCから分離したT細胞(1×105 cells/well)とPMA-処理されたhMSC(1×103 cells/well)をPHA(phytohemagglutinin、5μg/ml)と一緒72時間の間共培養をし、上澄み液中にあるIFN-γの水準をELISAを通じて測定した(図1のB)。PBMCから分離したB細胞(1×105 cells/well)とIFN-γ処理されたhMSC(1×103 cells/well)をODNと共に72時間の間共培養した後、上澄み液中にあるIgMの水準をELISAを通じて測定した(図1のC)。PBMCから分離したB細胞(1×105 cells/well)とI3A-処理された(treated)hMSC(1×103 cells/well)をODNと共に72時間の間共培養を実施し、上澄み液中にあるIgMの水準をELISAを通じて測定した(図1のD)。PBMCから分離したB細胞(1×105 cells/well)とPMA-処理されたhMSC(1×103 cells/well)をODNと共に72時間の間トランスウェル(transwell)を利用して共培養を実施し、上澄み液中にあるIgMの水準をELISAを通じて測定した(図1のE)。
MSCのケモカインをmRNA水準とタンパク質水準でそれぞれRT-PCR(図2のA)とELISA(図2のB)を通じて分析した。MSCのCCL2、CXCL10、CXCL12をsiRNAを利用してノックダウン(knockdown,KD)させた後、mRNA水準でRT-PCRを通じて確認した。トランスウェル(Transwell)を利用してMSCに対するB細胞の移動(migration)を測定し、下部ウェル(lower well)にはMSCを、上部ウェル(upper well)にはB細胞をシーディング(seeding)し、1.5時間後、FACS(fluorescence activated cell sorter)を利用して細胞数をカウント(counting)した(図2のC)。Culture-insert m-Dish35mmを利用して左側にMSC(70ml of 0.3×106 cells/ml)を添加し、右側にB細胞(70ml of 3×106 cells/ml)を添加し、タイム-ラプスイメージング(Time-lapse imaging)を利用して6時間の間撮影した後、代表的なB細胞の動きをグリーントラック(green track)で表示した(図2のD)。撮影したムービを時間帯別にスナップショット(snapshot)をとってB細胞の移動を観察した(図2のE)。スナップショット(snapshot)の白色ボックス内にあるT細胞の数をグラフで表示した(図2のF)。
Culture-Dish35mmを利用してMSC(0.2×106 cells/mlとB細胞(2×106 cells/ml)を添加し、タイム-ラプスイメージング(Time-lapse imaging)を利用して3時間の間撮影した後、代表的なB細胞の動きをグリーントラック(green track)で表示した(図3のA)。撮影したムービを時間帯別にスナップショット(snapshot)をとってB細胞とMSCの接触を緑色矢印(green arrow)で表示した(図3のB)。時間帯別にMSCに接触するB細胞の数を分析した(図3のC)。MSCと接触しないB細胞の速度とMSCと接触したB細胞の速度をグラフで表示した(図3のD)。1つのMSCに接触するB細胞の数とMSCとB細胞が接触するときの接触時間を分析した(図3のE)。
MSCにPMAを処理して24時間後、タンパク質を得、ウェスタンブロット(western blot)を通じてシグナリング(signaling)を分析した(図4のA)。MSCにPKC阻害剤(Go6983,1μg/ml)を1時間前処理し、PMAを処理した後、24時間後、タンパク質を得、ウェスタンブロット(western blot)を通じてシグナリング(signaling)を分析した(図4のB)。MSCにPKC阻害剤(Go6983、1μg/ml)を1時間前処理し、PMAを処理した後、PBMCから分離したB細胞(1×105 cells/well)とPMA-処理されたMSC(1×103 cells/well)をODNと共に72時間の間共培養を実施した後、上澄み液中にあるIgMの水準をELISAを通じて測定した(図4のC)。PMA-処理されたMSCの表面分子(surface molecule)のmRNA水準をRT-PCRを通じて分析した(図4のD)。PMA-処理されたMSCのPD-L1とB細胞のPD1の発現をFACSを通じて分析した(図4のE)。MSCにFasL blocking Ab(10μg/ml)(F)とPD-L1 blocking Ab(10μg/ml)(G)をそれぞれ処理し、PMAを入れた後、MSCとB細胞をODNと共に72時間の間培養した後、上澄み液にあるIgM水準をELISAを通じて測定した。PMA-処理されたMSCをsiRNAを処理してPD-L1をmRNA水準でRT-PCRを通じて確認した。PD-L1がノックダウンされたPMA-処理されたMSCとB細胞をODNと共に72時間の間培養した後、上澄み液にあるIgM水準をELISAを通じて測定した(図4のH)。MSCにPMAを処理して24時間後、トータルRNA(total RNA)を得、RT-PCRを通じて可溶性因子(soluble factor)を分析した(図4のI)。
PMA-処理されたMSCにPDL1 siRNAを処理した後、24時間の間共培養し、細胞をアネキシン(annexin)V-APCとPI-PEを利用して染色した後、FACSを通じて分析した(図5のA)。PMA-処理されたMSCにPDL1 siRNAを処理した後、24時間の間共培養した後、カスパーゼAb(Caspase Ab)を添加し、1時間後、FACSを通じて分析した(図5のB)。
PMA-処理されたMSCに対する治療効果実験を進めるために、自然発生ループス動物モデルであるMRL/lprマウスを通じて治療効果を検証した。MSCを4×104 cells/mouseの濃度でマウスに静脈注射し、投与時期は、マウスの発病が始める12週齢から1回注射した(MRL/lprマウス12週齢に対照群(希釈液)、MSC 4×104 cells/injectionを投与する)。動物実験の測定指標としては、毎週マウスの生存率と体重を確認し、2週間隔でanti-dsDNA、IgGを測定した。生存率(図6のA)と体重(図6のB)を毎週測定し、3週間隔で血清を分離してanti-dsDNA Ab(図6のC)、トータル(total)IgG(図6のD)を測定した。24週齢のMRL/lprマウスから脾臓(spleen)を分離して、細胞を獲得し、抗体を利用して細胞を染色した後、FACSで細胞表現型を測定した(図6のE)。その後、細胞のトータル(total)RNAを得た後、RT-PCRを通じて炎症性サイトカイン(cytokine)の発現を測定した(図6のF)。
MRL/lprマウスに対照群(希釈液)、MSC(4×104 cells/injection)を12週齢に投与した後、24週齢のMRL/lprマウスから腎臓(kidney)を分離してホルマリンで固定し、免疫細胞の浸潤性をDAB染色を利用して測定した。
Claims (12)
- タンパク質キナーゼC活性化剤(protein kinase C activator)で処理された幹細胞またはその培養物を含む自己免疫疾患の予防または治療用薬学的組成物。
- 前記タンパク質キナーゼC活性化剤は、ホルボールミリステートアセテート、インゲノール3-アンゲレート、ブリオスタチン-1、ホルボール-12,13-ジブチラート、プロストラチン、N-(6-フェニルヘキシル)-5-クロロ-1-ナフタレンスルホンアミドおよび5-クロロ-N-ヘプチルナフタレン-1-スルホンアミドよりなる群から選ばれる1つ以上を含むことを特徴とする請求項1に記載の自己免疫疾患の予防または治療用薬学的組成物。
- 前記幹細胞は、成体幹細胞、多能性幹細胞、誘導多能性幹細胞(induced pluripotent stem cells)または胚性幹細胞であることを特徴とする請求項1に記載の自己免疫疾患の予防または治療用薬学的組成物。
- 前記成体幹細胞は、間葉系幹細胞、間葉系ストローマ細胞(mesenchymal stromal cell)または多分化能幹細胞であることを特徴とする請求項1に記載の自己免疫疾患の予防または治療用薬学的組成物。
- 前記タンパク質キナーゼC活性化剤は、幹細胞のCXCL10の発現を増加させることを特徴とする請求項1に記載の自己免疫疾患の予防または治療用薬学的組成物。
- 前記タンパク質キナーゼC活性化剤は、幹細胞のPD-L1(programmed death-ligand 1)の発現を増加させることによってB細胞の細胞死を増加させることを特徴とする請求項1に記載の自己免疫疾患の予防または治療用薬学的組成物。
- 前記自己免疫疾患は、ループス(全身性紅斑性狼瘡)、関節リウマチ(rheumatoid arthritis)、全身性強皮症(Progressive systemic sclerosis,Scleroderma)、アトピー皮膚炎、円形脱毛症(alopecia areata)、乾癬、天疱瘡、喘息、アフタ性口内炎、慢性甲状腺炎、炎症性腸炎、ベーチェット病(Behcet’s disease)、クローン病、皮膚筋炎(dermatomyositis)、多発性筋炎(polymyositis)、多発性硬化症(multiple sclerosis)、自己免疫性溶血性貧血(Autoimmune hemolytic anemia)、自己免疫性脳脊髄炎、重症筋無力症(Myasthenia gravis)、グレーブス病(Graves’ disease)、結節性多発動脈炎(Polyarteritis nodosa)、強直性脊椎炎(Ankylosing spondylitis)、線維筋痛症候群(Fibromyalgia syndrome)および側頭動脈炎(Temporal arteritis)よりなる群から選ばれることを特徴とする請求項1に記載の自己免疫疾患の予防または治療用薬学的組成物。
- 請求項1に記載の組成物をヒトを除いた個体に投与する段階を含む、自己免疫疾患の予防または治療方法。
- 幹細胞にタンパク質キナーゼC活性化剤(protein kinase C activator)を添加して培養する段階を含む、免疫抑制剤の製造方法。
- タンパク質キナーゼC活性化剤(protein kinase C activator)で処理された幹細胞またはその培養物を被験体に投与する段階を含む、ヒトを除いた被験体の免疫反応を抑制する方法。
- タンパク質キナーゼC活性化剤(protein kinase C activator)で処理された幹細胞またはその培養物を含む薬学的組成物を個体に投与または服用させる段階を含む自己免疫疾患の予防または治療方法。
- タンパク質キナーゼC活性化剤(protein kinase C activator)で処理された幹細胞またはその培養物を含む薬学的組成物の自己免疫疾患の予防または治療用途。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2018-0137578 | 2018-11-09 | ||
KR1020180137578A KR102180111B1 (ko) | 2018-11-09 | 2018-11-09 | 단백질 키나아제 c 활성화제로 처리된 줄기세포 또는 그 배양물을 포함하는 자가면역질환 예방 또는 치료용 약학적 조성물 |
PCT/KR2019/014960 WO2020096340A1 (ko) | 2018-11-09 | 2019-11-06 | 단백질 키나아제 c 활성화제로 처리된 줄기세포 또는 그 배양물을 포함하는 자가면역질환 예방 또는 치료용 약학적 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022512987A true JP2022512987A (ja) | 2022-02-07 |
JP7277582B2 JP7277582B2 (ja) | 2023-05-19 |
Family
ID=70612532
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021525208A Active JP7277582B2 (ja) | 2018-11-09 | 2019-11-06 | タンパク質キナーゼc活性化剤で処理された幹細胞またはその培養物を含む自己免疫疾患の予防または治療用薬学的組成物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20220062345A1 (ja) |
EP (1) | EP3878458A4 (ja) |
JP (1) | JP7277582B2 (ja) |
KR (1) | KR102180111B1 (ja) |
WO (1) | WO2020096340A1 (ja) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5891906A (en) * | 1986-06-11 | 1999-04-06 | Procyon Pharmaceuticals, Inc. | Polyacetate-derived phorboids having anti-inflammatory and other uses |
CN101085983A (zh) * | 2006-06-06 | 2007-12-12 | 刘永详 | 自体干细胞、由其转化而成的目标细胞及其用途 |
KR20150144679A (ko) * | 2014-06-17 | 2015-12-28 | 가톨릭대학교 산학협력단 | Stat3 억제제가 처리된 간엽줄기세포를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물 |
KR20160109356A (ko) * | 2015-03-11 | 2016-09-21 | 이화여자대학교 산학협력단 | 자가 면역 질환 예방 또는 치료용 조성물 |
WO2018048220A1 (ko) * | 2016-09-07 | 2018-03-15 | 에스씨엠생명과학 주식회사 | 염증 자극된 중간엽 줄기세포를 포함하는 면역질환 또는 염증 질환의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7628988B2 (en) * | 2002-06-27 | 2009-12-08 | The General Hospital Corporation | Methods and compositions for treating type 1 diabetes |
EP2185689A2 (en) * | 2007-08-09 | 2010-05-19 | Genzyme Corporation | Method of treating autoimmune disease with mesenchymal stem cells |
KR20130111448A (ko) * | 2012-03-29 | 2013-10-10 | 가톨릭대학교 산학협력단 | 간엽줄기세포를 포함하는 자가면역질환 치료용 조성물 |
WO2014042292A1 (ko) * | 2012-09-12 | 2014-03-20 | 연세대학교 산학협력단 | 단백질 인산화효소 c 활성화제를 포함하는 줄기세포 부착 촉진용 조성물 및 줄기세포의 부착 촉진 방법 |
KR20150016117A (ko) * | 2013-07-30 | 2015-02-11 | 코아스템(주) | 인간 골수 유래 중간엽 줄기세포를 유효성분으로 포함하는 자가면역질환의 예방 또는 치료용 약제학적 조성물 |
KR102084974B1 (ko) * | 2013-07-30 | 2020-03-06 | 코아스템(주) | 인간 골수 유래 중간엽 줄기세포를 유효성분으로 포함하는 자가면역질환의 예방 또는 치료용 약제학적 조성물 |
KR20160109358A (ko) * | 2015-03-11 | 2016-09-21 | 이화여자대학교 산학협력단 | 면역 질환 예방 또는 치료용 조성물 |
KR101775262B1 (ko) * | 2016-01-11 | 2017-09-05 | 이화여자대학교 산학협력단 | 편도 유래 중간엽 줄기세포 또는 이의 조정 배지를 포함하는 피부 염증 질환 예방 또는 치료용 조성물 |
US20210128611A1 (en) * | 2016-07-25 | 2021-05-06 | Cellular Approaches, Inc. | Autologous and allogenic macrophages and monocytes for use in therapeutic methods |
KR101971323B1 (ko) * | 2016-10-17 | 2019-04-23 | 사회복지법인 삼성생명공익재단 | 면역질환 치료를 위한 고효능 줄기세포 선별방법 |
-
2018
- 2018-11-09 KR KR1020180137578A patent/KR102180111B1/ko active IP Right Grant
-
2019
- 2019-11-06 JP JP2021525208A patent/JP7277582B2/ja active Active
- 2019-11-06 EP EP19882207.4A patent/EP3878458A4/en active Pending
- 2019-11-06 WO PCT/KR2019/014960 patent/WO2020096340A1/ko unknown
- 2019-11-06 US US17/292,315 patent/US20220062345A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5891906A (en) * | 1986-06-11 | 1999-04-06 | Procyon Pharmaceuticals, Inc. | Polyacetate-derived phorboids having anti-inflammatory and other uses |
CN101085983A (zh) * | 2006-06-06 | 2007-12-12 | 刘永详 | 自体干细胞、由其转化而成的目标细胞及其用途 |
KR20150144679A (ko) * | 2014-06-17 | 2015-12-28 | 가톨릭대학교 산학협력단 | Stat3 억제제가 처리된 간엽줄기세포를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물 |
KR20160109356A (ko) * | 2015-03-11 | 2016-09-21 | 이화여자대학교 산학협력단 | 자가 면역 질환 예방 또는 치료용 조성물 |
WO2018048220A1 (ko) * | 2016-09-07 | 2018-03-15 | 에스씨엠생명과학 주식회사 | 염증 자극된 중간엽 줄기세포를 포함하는 면역질환 또는 염증 질환의 예방 또는 치료용 약학적 조성물 |
Non-Patent Citations (2)
Title |
---|
CELLULAR & MOLECULAR IMMUNOLOGY, vol. 5, no. 6, JPN6022020216, 2008, pages 417 - 424, ISSN: 0004779966 * |
幹細胞ハンドブック からだの再生を担う細胞たち 第12版, JPN6022042294, 2016, pages 1 - 12, ISSN: 0004893802 * |
Also Published As
Publication number | Publication date |
---|---|
US20220062345A1 (en) | 2022-03-03 |
KR20200053992A (ko) | 2020-05-19 |
WO2020096340A1 (ko) | 2020-05-14 |
EP3878458A4 (en) | 2022-11-02 |
EP3878458A1 (en) | 2021-09-15 |
JP7277582B2 (ja) | 2023-05-19 |
KR102180111B1 (ko) | 2020-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Okamoto et al. | Osteoimmunology: the conceptual framework unifying the immune and skeletal systems | |
JP2016094464A (ja) | 脂肪組織または胎盤組織に由来する接着性細胞および治療におけるその使用 | |
BR112013003169B1 (pt) | Uso de um agente terapêutico que inibe a ligação de células-tronco a tecido linfóide | |
JP5857373B2 (ja) | 自己免疫疾患を治療する方法 | |
WO2007082177A2 (en) | Myeloid suppressor cells, methods for preparing them, and methods for using them for treating autoimmunity | |
KR101520536B1 (ko) | 편도유래 줄기세포의 간세포로의 분화 방법 및 편도유래 줄기세포를 포함하는 간 기능 손상 치료용 세포치료제 조성물 | |
KR102025417B1 (ko) | 조절 t 세포 매개성 질환의 예방 또는 치료용 약학적 조성물 | |
MXPA05001992A (es) | Expansion ex-vivo de poblaciones de celulas de tallo, hematopoyeticas, en cultivos de celulas mononucleares. | |
Bao et al. | Toll-like receptor 3 activator preconditioning enhances modulatory function of adipose-derived mesenchymal stem cells in a fully MHC-mismatched murine model of heterotopic heart transplantation | |
JP7277582B2 (ja) | タンパク質キナーゼc活性化剤で処理された幹細胞またはその培養物を含む自己免疫疾患の予防または治療用薬学的組成物 | |
JP2021132638A (ja) | 改変されたナチュラルキラー細胞、医薬組成物、その製造方法及びその使用方法 | |
JP2022521027A (ja) | 治療に使用する細胞組成物を生成するためのガンマ・デルタt細胞のホーミング及び保持の方法 | |
Zhang et al. | Autologous mesenchymal stromal cells prevent transfusion-elicited sensitization and upregulate transitional and regulatory B cells | |
US20060018885A1 (en) | Methods for increasing HSC graft efficiency | |
Vogel et al. | Protocol to assess the tolerogenic properties of adoptively transferred dendritic cells during murine experimental autoimmune encephalomyelitis | |
Hosseini et al. | The regulatory role of eosinophils in adipose tissue depends on autophagy | |
Sigl et al. | RANK and RANKL of Bones, T Cells, and the Mammary Glands | |
EP3893898B1 (en) | Method of treating autoimmune and inflammatory diseases using b cells | |
JP7117704B1 (ja) | 糖尿病の予防及び/又は治療剤 | |
Wildberger | Therapeutic approach for Myasthenia Gravis using conditioned mesenchymal stromal cells | |
Shankar | Ex vivo expansion of human IL-10+ B cells with regulatory function | |
Huang | The role of MSCs in immunoregulation of macrophages during osteogenesis | |
Achita | Expansion and Characterization of Human Double Negative Regulatory T Cells | |
Murphy | Pro-inflammatory cytokine licensing as a strategy to enhance the efficacy of syngeneic mesenchymal stem cells for corneal transplantation | |
Carty | Biodistribution and Modes of Action of Multipotent Adult Progenitor Cell therapy in Murine Models of Transplant Rejection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210510 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220524 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220812 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20221011 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230208 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20230208 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230208 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20230228 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20230307 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230418 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230508 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7277582 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |